In the published article, there was an error in Figure 7 as published. During the mapping process, the wrong unit of concentration value was used. Previous mapping used mg/mL as the unit of concentration for the X-value, which is inconsistent with the unit used for the figure, and is now converted to μM. The resulting Ki-values change from 0.17 and 0.30 to 3.26 and 5.87, respectively. The corrected Figure 7 and its caption appear below.
FIGURE 7
Lineweaver-burk plot, secondary diagram of Ki inhibiting ivacaftor metabolism at different concentrations of nimodipine in RLM (A) and in HLM (B).
In the published article, there was an error in Table 2 as published. During the mapping process, the wrong unit of concentration value was used for Nimodipine. Previous mapping used mg/mL as the unit of concentration for the X-value, which is inconsistent with the unit used in the table, and is now converted to μM. The resulting Ki-values change from 0.17 and 0.30 to 3.26 and 5.87, respectively. The corrected Table 2 and its caption appear below.
TABLE 2
| Inhibitors | IC50 values (μM) | Inhibition type | Ki (μM) | αKi (μM) | α | |
|---|---|---|---|---|---|---|
| Nisoldipine | RLM | 6.55 | non-competitive inhibition and competitive inhibition | 3.35 | 8.48 | 2.53 |
| HLM | 9.10 | non-competitive inhibition and competitive inhibition | 3.92 | 35.40 | 9.03 | |
| Nimodipine | RLM | 4.57 | competitive inhibition | 3.26 | ||
| HLM | 7.15 | competitive inhibition | 5.87 |
The IC50 values and inhibitory effects of nisoldipine and nimodipine on ivacaftor metabolism in RLM and HLM.
In the published article, there was an error. During the mapping process, the wrong unit of concentration value was used. Previous mapping used mg/mL as the unit of concentration for the X-value and is now converted to μM. The resulting Ki-values change from 0.17 and 0.30 to 3.26 and 5.87, respectively.
A correction has been made to 3 Results, 3.3 Nisoldipine and nimodipine inhibited ivacaftor metabolism in RLM and in HLM through different inhibitory mechanisms. This sentence previously stated:
“The Ki values were 0.17 and 0.30, respectively (Table 2).”
The corrected sentence appears below:
“The Ki values were 3.26 and 5.87, respectively (Table 2).”
The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
cystic fibrosis, ivacaftor, nisoldipine, nimodipine, drug-drug interaction, pharmacokinetics
Citation
Xia H, Xu X, Chen J, Wu H, Shen Y, Chen X, Xu R-a and Wu W (2024) Corrigendum: Inhibitory effects of calcium channel blockers nisoldipine and nimodipine on ivacaftor metabolism and their underlying mechanism. Front. Pharmacol. 15:1495855. doi: 10.3389/fphar.2024.1495855
Received
13 September 2024
Accepted
23 September 2024
Published
27 September 2024
Volume
15 - 2024
Edited and reviewed by
Junmei Wang, University of Pittsburgh, United States
Updates
Copyright
© 2024 Xia, Xu, Chen, Wu, Shen, Chen, Xu and Wu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wenzhi Wu, wwzljy@163.com; Ren-ai Xu, xra@wmu.edu.cn
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.